have come back with a much better offer and astra zeneca have turned it down. what is going to happen now is that it is dependent on what astra zeneca shareholders do next. >> do you think there is a chance that astra zeneca shareholders will turn around and put pressure on the board of the company to go back to the negotiating table to engage again with pfizer? >> there is certainly that possibility. but you have to ask yourself the the astrayou know, zeneca board basically turned the offer down flat. it is hard to imagine they would do that unless they were reasonably confident they had the backing of the majority of the shareholders involved. the ceo has come out this afternoon and said if shareholders don't like what i've done, they can always play someone over me. their votes over me. we will see what happens next. >> was their politics involved, or was this a question of an offer not being big enough for astra zeneca's tased -- ta ste? >> i think it was a combination of the two. i think they were holding up for about 60 pounds per share. but the environme

beingrse, after zeneca is direct and upfront.neca is being direct and upfront. >> if we think about the overall position, maybe nothing might happen between now and the 26, do you have the view that pfizer could come back with a hostile challenge six months from now? is that your baseline scenario? , there are opportunities course, six month later, our view is that it depends on the valuation of astra zeneca. , the pipeline progress and the aspects of pfizer not being changed. also, the pressure on pfizer to focus on smaller units. that looksindustry towards scientific leadership. >> we have spoken with a number of people. praised the ceo and staying independent. he has a lot to deliver in the next six months, if he is going to be credible in his defense. well, the investor log is in favor of them. forced.stry is have a good way in a short length of time to move on that strategy. key to puts very together companies that are big. away in theight industrials. goes right away in the industrials. >> we will have you back on. pulse is

. -- hans nichols is covering pfizer's bid for astor zeneca. david tweed is in berlin covering airbus and earnings are breaking now for that business. big with "countdown" for interviews. first, an exclusive interview live from the goldman sachs india idea summit. who would hear from the head of international asset management division, coming up later. ceo, we will speak with the peter long, right after those earnings break at the top of the next hour. we will also get numbers from easyjet as well as insight into those numbers from the ceo of the low-cost airline. be releaseds will in about 58 minutes. sweetens planning to its bid for astor zeneca as the ceos of both companies face their first joint trial and the u.k., testimony. hans nichols has the details from westminster. hans? anna, good morning to you. we will find out after this hearing potentially about a sweetened bid from pfizer, increasing it, but they will not make a decision to go hostile until they see how the committee hearing goes. we will get a sense of how hostile or friendly

hans following pfizer and after zeneca ahead of key hearings today. more on that. >> we like the smell of a parliamentary hearing first thing in the morning. to convincebe able the public and this parliament that it is about jobs and research, not just taxes? in a few minutes, we have an important interview with a labor and the -- mp. we will get a sense on just how hostile it may be. and she hasis here her eye on the airline industry. easyjet reported earlier. rex it did. bang in line with expectations is not good enough to send the share price higher. they said it could potentially decrease a little bit. once again, read tax is better that -- pretax is better than expected. they are becoming more profitable. they are taking on amazing technological leaps and bounds. drones, 3-d glasses, just to make sure they can analyze any disruptions to the airplane, any concerns, inspect planes for damage faster. scrapping paper manuals, they are set to save half a billion pounds per year. eight, cut a kilo of w 20,000 pounds per year in terms of fuel. amazing.

in an effort to create the world's largest pharmaceutical company pfizer had been chasing astra zeneca since away back in november now pfizer last proposed a deal for the company in november valued at one hundred twenty eight billion dollars billion with a b under u.k. takeover rules astra zeneca was able to run out the clock on monday's deadline for reaching an agreement the decision ends a month long public fight between two of the world's biggest pharmaceutical companies the battle sparked political concerns on both sides of the atlantic over jobs and corporate tax maneuvers british rules now require enforced cooling off period astra zeneca could reach out. pfizer after three months and pfizer could take another run at its smaller british rival in about six months now pfizer walked away from the table with two hours to spare on monday morning and its decision to abandon negotiations had been widely expected after astra zeneca refused its final offer of ninety two dollars a share pfizer c.e.o. ian reid said in a written statement quote we continued to believe that our final proposal

takeover court in combination with astra zeneca.t going to report the diluted guidance that there are reporting other guidance. that is the specific wording of their outlook. >> as we heard in the last hour, the top rated -- this is all about pfizer getting closer to cancer drugs, which it would get reasonably by buying astra zeneca. astrazeneca has denied the bit twice. >> i go down to the basics. >> viagra. to let us know o le you don't need it. >> it continues to see buybacks of $5 million -- of five dollars per share. to other headlines. another recall for general motors. thattime it is 52,000 suvs flawed a fuel gauge software. gm is being investigated over why it took so long to recall 2.5 million cars with faulty ignition switches. siemens is on the verge of selling its airport units. this is according to people familiar with the talks. siemens makes partial unit baggage handling systems. win.g on the win comes months after city created a unit that combines custody with financing and fund services. that is this morning's compa

you think astra zeneca mistake here? down to thet boils investment.usly, the board is making the case that the future of astrazeneca as an independent game -- as an independent company outweighs the short-term gain of profit. certain shareholders support the board and others are more frustrated. that is basically how things the, depending on investment. >> what would you do if you are a pfizer ceo -- if you were the might you start spinning off one or another division within pfizer? he look for another target? obviously, they have shown their hand. they had an interest and they can launch an acquisition again. people know,y, as they were very keen to embrace astrazeneca into their group. a lot of questions going forward, but there is a someegy, maybe, to court executives at esther zeneca and have discussions along the way. next for theat is company? they made the case that they are strong enough to go it alone. do think they could potentially be looking at an acquisition in the future to try to bolster the given the activity they have had over the las

after zeneca shareholders is thinking this doesn't get done. >> do they need this more than pfizer does>> they said all along that they don't need this. >> if you look at the stock price they did. to jump back up to where it was, they need it. saying.what they are they were happy before and can do it on their own. they don't need a big company to be a partner like pfizer. they will go alone. pfizer will not be able to do this. we will see how all these big claims about astrazeneca plays out. >> is there any place else for pfizer to turn? what will he do with all that cash? >> there aren't that many places for them to turn. they were looking for three different things. they wanted big cost synergy. they wanted to invert themselves and get out of the corporate tax rate in america. they wanted to find somebody that had a pipeline they could use. there are not that many big pharma companies that have those three things. there aren't that many candidates. astrazeneca was probably the best option for them. >> thank you so much drew talking to us about pfizer and astrazeneca. we will hear from

astra zeneca says the bid is not enough. to 60 raises the bid billion pounds before being turned down once again. game over or not? >> i've talked to one of my andnds on the sell side they have talk to the company directly and it sounds like they do not want to carry on business. it is not just about the price. there talking about social responsibility. that resonates very well with the political climate and the way this has been handled in the public domain. i think it is done for now. i don't know how many more degrees of freedom pfizer has in terms of its movements, at least for the next three to six months. >> what are pfizer's options here? there are no other big pharma companies for them to buy. >> i don't know whether you would call it hostile if they try to reach out to shareholders. i don't know if that qualifies as hostile. there is still four trading days left -- are still four trading days left. they could sit around the table and figure out -- of -- they have kind of sat around the imaginary table. >> the two-ho

drugmaker, has abandoned its efforts to take over the british pharmaceutical company, astra zeneca. pfizer withdrew its latest unsolicited offer of nearly 120 billion dollars. astra zeneca's board rejected pfizer's offers four times over the past few weeks, saying the bids were not high enough. pfizer would not say if it will try again... but industry analysts expect another move in a few months... after a mandatory three-month waiting period. time for sports. a year ago, the blackhawks were down three- one to detroit before winning three straight to advance in the playoffs... now they'll have to do it again. patrick kane moved to the top line with jonathan toews in game four. hawks on the power play early... marian hossa makes a nice move in front but jonathan quick makes the save... hawks went oh- for- three on the power play still scoreless later in the period and a kings' power play now... corey crawford gets screened and jake muzzin scores his fifth of the playoffs. hawks down two later in the period... kings on another power play and dustin brown scores on the wide open net. b

atra zeneca's board faces backlash after rebuffing a takeover offer from rival drugmaker pfizer.chroders is urging them to restart the talks. the company says it was disappointed by astrazeneca's quick dismissal of the bid on monday. will fight ays it ruling. a competition watchdog has upheld the ruling, and it could ink banned by lui the end of the year. dominantdog says its position between france and the u.k. could lead to higher fares. that is business news for now. i will kick the cannes back to you. >> you could not resist, could you? [laughter] thanks for that. it is time for our rendezvous with cannes. meeting belgium's celebrated filmmakers, the dardenne brothers, in the running for the festival's top prize. ♪ >> welcome back to a rather windy cannes film festival for today's cannes rendezvous. it is a tough enough feat to win the palme d'or once, even tougher to win it twice. only a handful of directors have achieved that in the entire festival. today we meet a pair of directors who have done just that. belgium's dardenne brothers are back with a film called "two days,

ifs as a tra zeneca would take this, there could be a bid. there's a branch that one can relieve in the current statement and this is the point when they start considering this in itself fairly usual. so there's a slight bit of wrinkle room, but having said that, if you look at what's happening with the share price this morning, i don't think they believe that pfizer is going to come back with quite a substantial offer because that would be nearly twice what it was before the bid came in. >> the other thing is you look at the statement from astrazeneca, it is not just the price, that's one of three key points. the other two points aren't going to change. it would be rather bizarre to say this isn't just about the price. astrazeneca shareholders are big in the company and are acting on behalf of their personal interests as well as their shareholders interest. >> they should be in line, theoretically. >> of course, that's the whole idea of share rewards, but there doesn't seem to be a lot in there ability having re-examined the strength of astr

lawmakers amid plans to sweeten its after zeneca takeover bid. >> socgen sets the bar high. the bank targets higher profits helped by lending in russia and africa. thisill hear from its ceo hour. >> and we speak with the cofounder of skype and the former head of the world bank. we are live at goldman sachs' asset management ideas summit. hello. welcome to "the pulse," live from bloomberg's european headquarters in london. i am mark barton. >> and i am caroline hyde. >> we begin with our top story. pfizer said to plan a sweet and -- a sweet takeover bid for astrazeneca. westminster is at with more on what we can expect. the countdown continues great -- the countdown continues. >> the countdown continues from that conversation we had earlier with a labour mp. clearly, the ceos are going to face some hostile questions about what their intent is. why are they doing this? are they doing it for tax reasons? there is a different tax regime in the u.k. versus the u.s. or are they doing it because it makes sense for their investors, their boards him a their shareholders, and they wan

pharmaceutical giant astra zeneca. this is about 35 minutes. >> order. questions for the prime minister. jonathan edwards. >> number one, mr. speaker. >> thank you, mr. speaker. this morning i had meetings with colleagues and others and in addition to my duties, i shall have further such meetings later today. >> u.k. has 104 billionaires. london has 72 billionaires, top city in the world. is the prime minister concerned? that most of our people are getting filthy rich? >> what is worth while is the massive fall in unemployment and increasing employment that we have seen across our country. in terms of wales today, unemployment has fallen by 5,000 and fallen by 25,000 since the last election. that means in wales, 59,000 more people in work. in terms of making sure that the richest in our country pay their taxes, actually we see the richest 1% paying a greater percentage of income tax than ever they did under labour. what we are seeing is a broad-based recovery and i want to make sure everyone in our country can benefit and we are cutting people's taxes an

. ♪ astra zeneca shares takeover bid is too low. buying directv for $50 billion.nk enlists in a m. -- capital hike. morning to our viewers. >> good m

pfizer says it will not go directly to ask zeneca shareholders with a also offer.ca shareholders a hostile offer. credit suisse -- the chairman says there may be an agreement in the case as early as today. according to a person familiar with the matter, credit suisse would plead guilty and pay 2.5 ilium dollars in penalties. >> -- billion dollars in penalties. -- $2.5 billion in penalties. will be share dilution, there will be less profit, and obligatory interviews painting a picture of management and control. hans nichols spoke today to mr. learn?hat did you >> i learned that he is in control. there is a certain choreography to these interviews. jain try to say is this is the right time to get capital and he thinks the market is ripe for it, that is how he put it. >> we decided we would get one step ahead, with a capital buffer. and the innovation position. why $1cond question was billion. ofstarted with the ratio 9.5, then up to 11.8, which we think is a very healthy buffer. tom, i would suggest that they have full floors of people in the deutsche bank building b

bind after zeneca would boost the biggest pharmaceutical company. both are trading to the downside.pedia. more people use expedia in their travel plans. expedia revenue and jumping 19% year ago to $1.2 billion. earnings did fall a bit. we will see shares down 4% so what does $1 million get you in los angeles? we are going to show you coming up next. stuart: wall street journal poll finds contrary to what dr. keith tableau told us, perahia's of social media is not changing the way we interact in the real world. loren has details. >> very surprising. we are not only socializing online, we pay our bills online, we shop online yet look at this. 58% of people still say they have family dinner at least we 5 times a week. about the same number as 15 for years ago. 60% said the same in 1999 and another part of this poll do we know our neighbors? 69% say they currently no and talk to their neighbors and 73% 15 years ago. peter: when a family dinner situation we all sit around with a cellphone. i got myself on in my pocket when i talked to a neighbor. >> you would imagine even though you are

finally the mother of all form a deals, this is getting crowded, $106 billion bid for the uk after zeneca astrazeneca. what is behind all this consolidation in the farm a space? joining me now in a fox business exclusive, citigroup institutional client group vice chair. is there a building on fire suddenly everybody is rushing to do m&a deals? what is going on? >> potentially the next m&a. everyone knows the stock market is close to an all-time high. everyone knows corporate balance sheets have significant cash, everyone knows interest rates are close to all-time levels of low. the real question is how the market life looks at the equities. if you look at the way the equities have performed, acquirer stocks have gone up. they usually are down. if you go back to aol, time warner, other transactions, they deteriorate. now they're going up because they are very focused transactions. the pricing being rational. they believed many ceos have decided doing acquisitions and expanding their business is a much better use of capital stock buyback. liz: they must be able to feel they can borrow my to

pharmaceuticals giant pfizer trying to take over its british rival as zeneca.oing for many, many months. it hasn't gone through. that deal was rejected by shareholders. earlier i spoke to one of the big shareholders, abidine asset management. the chief executive of that firm said that is a perfect example of how business and shareholders are looking at the long-term implications rather than simply a short-term profit for a premium on share price. this is what he had to say. >> we backed the as seneca board and the rejection of pfizer. it's a rare example of the long-term view being taken over the short-term view. so the company outlines a case that they had a great long-term future and we would be better rejecting the bid even though we did take a hit between the sort of 55 pounds and the 40 pounds it is today. so it's quite a decision for a fund manager, especially as i say, if you need the performance to meet your quarterly figures. it was a brave decision, a very brave decision by the board as well as the ceo because he's got to produce the good long-term nu

froms stra zeneca's level last night they're at $99 a share. on its face, in a world rational and world not in this uk and bound by the uk takeover laws hard to understand, that would seem like a bridgeable gap to me. from a negotiating gap, i think this is bridgeable. the question is what do the uk laws allow. that's not clear to me. some people saying pfizer is legally restricted paying more than this. others say, no, no, if astrazeneca is agreeable, they can raise the bid. i tend to think of the latter. that kind of a spread should be bridgeable. >> the thing is whether astrazeneca does come back and negotiate. without that happening under the uk rules nothing can really happen for at least six months, right? >> yes. that's my understanding as well. astrazeneca has to -- for this to continue, astrazeneca has to change its process and invite pfizer in the process. i think it's in the hands of astrazeneca shareholders. i think that's what pfizer is doing. i call this effectively a friendly-hostile bid. not actually going hostile. by pfizer put

after a bunch of other pharmaceutical deals and pfizer's so-far unsuccessful attempt to buy astra zenecaor $106 billion. although i'm guessing that price is going to go. >>> if you're middle class in america, there's almost no room for mistakes. one financial slip and you could fall to the bottom. my look at middle class families trying to rebuild the american dream continues tonight with a single mom putting a brave face on her struggle: >> it's the long, long-term struggle of noting able to have basic needs met. basic needs, as in food in the refrigerator, shoes to work in. >> she's down, but she's not out. i'll tell you how she's giving success one last shot and taking a big gamble with her small business, coming up. >> attracting customers, targeting business opportunities, and finding new business are among the top challenges facing small business owners in the u-s, according to a new gallup survey. but it's kind of according to anybody whoever owned a small gins. jodi bowlin, the owner of a struggling gift shop in knoxville, tennesee is hoping she'll be able to attract new customer

nation's biggest drug maker promised it will not go hostile by taking its offer directly to astra-zeneca'sers. >>> in health headlines this morning america's pediatricians are recommending expectant moms to take a supplement containing iodide. the iodide is needed to make the thyroid hormones required for children's healthy brain development before and after birth. experts recommend pregnant and breast-feeding women get 290 micrograms of iodide per day. one more thing that a pregnant woman needs to take. my goodness, the supplements. >> it's true. i talk to my wife about this because our doctors talk to her, take more iron and things like that. we never heard of iodide. when you think about it is iodized salt. the salt with the umbrella, the woman with the umbrella. but so many people are using kosher salt and others. even when you use take out food. >> it is because of the health scares associated with table salt. you don't want to have heart disease, you don't want to have cholesterol and everything according to the health experts is related to the salt intake. >> seems like there is one

after a bunch of other pharmaceutical deals and pfizer's so-far unsuccessful attempt to buy astra zenecaor $106 billion. although i'm guessing that price is going to go. >>> if you're middle class in america, there's almost no room for mistakes. one financial slip and you could fall to the bottom. my look at middle class families trying to rebuild the american dream continues tonight with a single mom putting a brave face on her struggle: >> it's the long, long-term struggle of noting able to have basic needs met. basic needs, as in food in the refrigerator, shoes to work in. >> she's down, but she's not out. i'll tell you how she's giving success one last shot and taking a big gamble with her small business, coming up. >> you followed their journey across the border >> it was heart wrenching... >> now see how it changed the lives of the people involved. >> i didn't go back to the person that i was before i left... >> an emotional borderland reunion >> this trip was personal to me... this is real... >> long held beliefs >>...illegal in mexico too.. >> learn the language! come here... >>.

after a bunch of other pharmaceutical deals and pfizer's so-far unsuccessful attempt to buy astra zenecaor $106 billion. although i'm guessing that price is going to go. >>> if you're middle class in america, there's almost no room for mistakes. one financial slip and you could fall to the bottom. my look at middle class families trying to rebuild the american dream continues tonight with a single mom putting a brave face on her struggle: >> it's the long, long-term struggle of noting able to have basic needs met. basic needs, as in food in the refrigerator, shoes to work in. >> she's down, but she's not out. i'll tell you how she's giving success one last shot and taking a big gamble with her small business, coming up. >> on techknow... >> we're heading towards the glaciers >> a global warning >> is there an environmental urgency? >> that is closer than you think... >> even a modest rise, have dramatic impacts on humankind. >> how is it changing the way you live today? techknow... every saturday, go where science meets humanity... >> this is some of the best driving i've ever done... ev

is it getting stuck in with pfizer and astra's zeneca with the british interests or standing back, doing nothing apart from playing politics? that is the point. i am clear what the british interest is, it is british jobs, british r&b and i will do everything to make those guarantees the we received and he would have gotten nothing. as we do so let us remember this, 175,000 employed in life sciences at our country because we are an open economy that encourages investments. eli lilly, and no vargas, johnson and johnson have chosen to invest here because it is a great company to come and do business. >> the problem is his assurances are inappropriate. not my words but the words of the press and other royal society. his assurances i useless and there is no guarantee, now let's talk about jobs on jobs. the head of pfizer said yesterday, quote, there will be job cuts somewhere. assurance that these job cuts won't take place in the u.k.? we have assurances on the percentage of r and d that will happen here, investments in cambridge. if he is arguing do we want further assurances, yes we do. do

astra zeneca. i'm jeff glor, cbs news. those little things still get you.dalafil for daily use helps you be ready anytime the moment is right. cialis is also the only daily ed tablet approved to treat symptoms of bph, like needing to go frequently. tell your doctor about all your medical conditions and medicines, and ask if your heart is healthy enough for sex. do not take cialis if you take nitrates for chest pain, as it may cause an unsafe drop in blood pressure. do not drink alcohol in excess. side effects may include headache, upset stomach, delayed backache or muscle ache. to avoid long-term injury, get medical help right away for an erection lasting more than four hours. if you have any sudden decrease or loss in hearing or vision, or any allergic reactions like rash, hives, swelling of the lips, tongue or throat, or difficulty breathing or swallowing, stop taking cialis and get medical help right away. ask your doctor about cialis for daily use and a free 30-tablet trial. natural energy from tea packed with real juice from delicious fruits and veggie

to takec we're about up, pfizer's bid for london-based asterix zeneca -- astrazeneca.that corporations can and should do everything possible to minimize their tax interest -- in the interest of their shareholders. from london's point of view, it is not a lose lose proposition. this is a mostly win proposition. the harder questions will come and the u.s. congress. you want to see pfizer give job reassurances in the u.k., but will it do so here in maryland and delaware? congressg risk is that takes steps to prevent deals like this from happening, possibly backdating or making retroactive legislation to make pies are able to buy after that i can -- pfizer not able to buy astrazeneca. to's put this question potomac research groups chief political strategist. that democrats and republicans are at loggerheads over everything about what is the chance that congress could act to stop this deal from going forward? >> is an election year, and democrats need issues. they're itching to take a stance on this. chances are slim we could get anything through both houses, but if there a

after zeneca stock hit a high yesterday. we have been looking into the details.s this going to seal the deal? >> will it bring astrazeneca to the negotiating table? pounds, $106. they rejected the first one. this will not be the final set of terms, there would be some more negotiations. just think of the mastery of dealmaking. 24 hours, hitting the city, the square mile. those are the two key drivers. >> that matters because a lot of shareholders are dual shareholders, aren't they? >> absolutely. shareholders,jor those are the boys and girls that get that over the line. if you get that done, you have a better chance of getting that over the line. blackrock, wellington, they own over 20% of the company. it is about getting momentum. the chairman defended the original backing away from the on stock.e valuation we understand there would be more cash on the steel and that the offer will be raised. >> will there still be obstacles in place. what are they? >> parliament. the parliament of public opinion. building was to speak to pfizer. how do want to do business. he h

he dealt with job losses and sweeter in the wake of the astra and set a coverage zeneca mergerd that took place 15 years ago. carney take action? we will discuss that and other topics right after the break. ♪ >> time for today's company news. the p faces billions of dollars in additional payments after it failed to convince an appeals court that the companies being forced to pay claims that aren't directly related to the gulf of mexico oil spill. the u.s. court of appeals thatted bps contention they had misinterpreted the agreement. google is acquiring mobile device software start up divide. trend caters to a growing known as bring your own device, where companies let employees use their own mobile devices while using third-party software to separate business and personal functions. go pro has filed for its initial public offering. go pro posted a $60.6 million profit last year, almost double what it earned in 2012. while most of that was acquired through cameras and accessories, it plans to as edition itself as a media company, today's filing shows. time in london is 18 minutes past

one of the selling points of the pfizer-national zeneca deal was the tax advantage, that they could take over a smaller foreign company, and effectively and operations overseas reduce the u.s. tax burden, even on earnings here in the united states. that was controversial, and it was a selling point for the company, the shareholders, as to why the deal made sense. the deal blew up, but it was not because the tax break. the tax break is still here. 14 companies have announced or completed their plans to use the inversion tax break since 2012, and there are a number of other companies considering it even after the outcry over the pfizer-astrazeneca deal. >> isn't their opposition? >> there is bipartisan opposition, but not bipartisan action. your two top democrats in the u.s. senate that would forward, ron wyden and carl levin, both of them are outraged by the proposal, saying he needs to stop, and they plan to introduce havelation that would blocked the pfizer deal had it moved forward, but there is no republican cosponsorship for their efforts. proposal on the table that would require the

expecting great performance from d after zeneca drug pipeline down the road. other thing he may try to do is make asked -- make acquisitions of its own, showing is willing to set the agenda and eight: -- and by growth. owth.d buy gr >> matt campbell with us from london. the deal is dead but perhaps not for good. coming up, amazon but publishers know who is the boss. a fight over how much it should get paid for e-books. we will be back in a couple of minutes. ♪ >> the plot is thickening between amazon and one of the world's leading publishers. amazon is slowing deliveries over a contract dispute. caught in the crossfire are authors jk rolling and james patterson. and jamesing patterson. we speak with a former magazine publisher. also with us is the president of the authors guild. is this what happens when jeff bezos decides to flex his muscles? >> this is what happened when jeff bezos looks at an and can'tan industry figure out what to do in the digital age. agree that the book publishing industry is an he suggests?hat >> i would not call it antediluvian but i

what laster zeneca do? could become -- what will astrazeneca do? target or a creditor -- could it become a target or a predator? >> they have come out with several promising cancer drugs in the past couple of months. bit moreed a little money. the question for pfizer is what do they do since they have not been able to buy up astrazeneca? people have mentioned other names. the problem is that they are based in the u.s. b the logic was that astrazeneca , with ad in the u.k. lower corporate tax rate. >> investors believe there is not going to be another bid and that this bid will not be successful. he said he would recommend 58.55.ion if it got >> he said, why did you lay out , why did- i said you lay out a price? he said it was for shareholders. >> shareholders were hoping that they would at least enter into discussion. saidiggest shareholder they would be fine with it. >> it depends if you have a short-term or long-term horizon. >> do you believe that these projections for the drugs that astrazeneca has in? let's bring in more with the russian prime

as day tog continues up after zeneca takeover hearings. he is avoiding detail on his job pledge. >> welcome to countdown. >> welcome to the program. bloomberg reporters are standing by across the world ready to deliver the stories that will drive your day. john is looking ahead to the bank of england's inflation report. >> john is in hong kong with the details on the rise in chinese david isd in berlin, focused on angela merkel's comments on the ukraine. >> we will tell you about some of the interviews we are bringing you today. we have an exclusive interview with the russian foreign minister coming up at noon london time. in conversation with them and we will bring you that conversation live from moscow. >> the bank of england will publish its reports.this morning what clues might hold about the policies? jon ferro will tell us what the market is thinking and what mr. carney might be preparing to tell us. >> you were going to get forecast growth and inflation. that is the only two things people care about is rate hikes. the bank of englan

there are some problems with pfizer trying to bright as her zeneca in the ukp at all of these mergerlk about. we will see more from pfizer and astrazeneca as the week goes on. let's move to the ukraine. a criminal farce was held in chaos. now some semblance of legitimacy after some sort of referendum. how vladimir putin adapt and adjust his message. she is author of the limits of partnership, u.s. russian relationships in the 21st century. good morning. what has changed over the weekend for vladimir putin? think vladimir putin can say they voted for self-rule or independence. he said we have to have a civilized implementation of the vote. what changes for him as he can go back to the u.s. and europeans and current ukrainian government and sale you guys have to sit down, you have to include these people in roundtable talks. we have to move forward to a federal solution in the ukraine. it has given him a little time. not to intervene anymore. >> we saw emerge three over the weekend of mr. putin and defense forces celebrating a world war ii victory. then we saw a walk by in crimea. that

. >> than pfizer -- zeneca as well. >> shareholders are pushing pfizer to consider a deal again. >> alexh us. i need a briefing to get to the weekend. mr. putin is in china. he had a victory lap coming off of china. >> russia and china signed this is sort $400 billion gas supply deal last week. plan to show this options whening things turn sour. and is in st.ck petersburg and ryan chilcote is there. then he looks to ukraine. what is his fondest outcome monday morning? putin says that the election only helps to solve the crisis if the rights of all ukrainians are guaranteed. what that means, what that is code for is an extensive level of decentralization of ukraine that would make the kiev government powerless to control its own destiny. that basic clash will remain even after the election. if we had a u.s. presidential election and we had 16 people die in a gun battle in new england three days before it, can you call that a stable place to have an election? >> i think they can. this question of whether the election has been disrupted is in the eye of beholder. the beholder at the moment

now what happened is you are seeing a group of astra zeneca saying hold on, wait a second -- maybe youback to the table. >> there is a mandatory three-month cooling off period. >> we have u.k. takeover panel rules. this is dead for the time being. three months from now, if astrazeneca asks pfizer took him back, pfizer can come back to the table and they can restart the talks. astrazeneca does not ask, they have to wait six months. this will go on until late summer, potentially into the late fall if we keep going through. >> do you think this was about concern over astrazeneca's pipeline only goes out six years . the concern about the loss of u.k. jobs. or was it a pride thing, asters and because the number two drugmaker in the u.k. and lawmakers did not want to see that go to an american company. >> it is a little bit of everything. want to be saying we independent. their ceo wants a chance to prove he can hold down promises he has made. pfizer is sometimes seen by u.k. big, bad,s as a conquering american company that was going to ruin everything. political issue in britain, sweden, an

astra zeneca tells pfizer to stick it. pfizer stays in america. nasty pull for the president. "varney & company" about to begin with a surprise guest. he is a trial lawyer who just got the biggest payday of his career. this time, i am on his side. ♪ stuart: check out the market. i am going to call it but a much dead flat. no deal for astrazeneca peered that company has rejected a final $121 bid from pfizer. astrazeneca taking the hit. down. pfizer up just a fraction. pfizer could go back in six months with another bid. the market is telling us that that is not going to happen. at&t will try to buy direct tv for nearly $49 billion. right now, both of those stocks are down. here is the reason that i think at&t wants to go for direct tv. that is the value of live sport events. nfl sunday ticket, and i'll be extra innings, nba league pass, international soccer. i say this proposal is all about live sporting events. protecting people. am i right push her mark. >> you are right in part. i think this is a direct response to the comcast time warner deal. stuart: okay. both stocks are

investors to own half of these companies, should throw a wrench into mergers like pfizer with astra zenecad. stuart: they will do what you want. rumblings that somebody might be wanting to buy pandora so the stock is up. >> the stock is up 1.5%. don't forget we heard apple, streaming video, video content, streaming use it, all these areas that continued to grow. and pandora is in this area, and nick 1.6%. of grated raymond james and others. a loser, 9% lower. it is up 4% this month so maybe some people do think, we talked about this in the last few weeks so keep an eye on this. stuart: europe's top court says google must respect people's right to be forgotten, the ability to remove personal information from search engines. is this good or bad for stock? >> it is good for the industry in terms of tech. if this is indicative of what is going on in europe that will work its way over here fairly quickly and that might mean there are sites that will evolve and people will just opt out of allowing certain content to be passed along. in terms of advertisers they won't see the target audience they

companies here in the united states and here are some companies right now you know pfizer and astra zeneca actually are getting together in order to potentially avoid tax pfizer's american company they want to buy astra zeneca which is the u.k. in order to therefore in the u.k. and avoid tax so what you would have there for a country companies from the u.k. and elsewhere coming over to the united states and trying to set up shell companies here to run their taxes through it zero percent and then pass it back into those their countries not simplifying the situation right only making it was creating a tax haven for the united states really at the end of the day the whole double taxation thing is complete nonsense because at the end of the day a corporation in order to derive benefit from the incorporating right economies of scale cosmic scope we also saw the fact that during the crisis you know there was mortgage fraud perpetrated by people. some of the too big to fail banks we have in the global where they went under enormous prosecute for those things that the corporate veil right there yo

just great so what is the deal here advisor trying to buy astra zeneca i mean would pfizer really buyanother company just to cheat on its axis well of farms or is one of those companies that. uses our infrastructure they use our police departments they use our fire they use they take advantage of the in i spied sake of national institutes of health in it basically stealing from them to make their new drugs we give them patent protection in the federal system we give them treated protection they use our military they they they then take taxpayers' money in addition to all that taxpayers' money they take taxpayers' money because we use their product to give to medicare and medicaid in the v.a. so they make a ton of money by taking from taxpayers now their position is it's a one way street in reed who's the c.e.o. and really is really part of the hall of shame of c o o's he says look i want to take everything from the united states but then i want to go to the u.k. because i don't want to pay any taxes now this is after those same taxpayers you and me that i'm talking about have already

so astra was british and zeneca swedish. >> the biggest investors on the planet are unveiling what theynd selling. dominic has been going over some of those. he has the lights. >> last hour we told you about some of the highlights from warren buffett, john paulson. a couple of interesting themes, how these like verizon stock. other next three starts off with a man that may have given a nudge to the market down turn after hedge fund manager app look sa said not to be too freaking long. he notably sold out of verizon. he made interesting trade in the higher growth momentum stocks. he took a position in facebook as well as online travel company expedia. he got completely out of computer storage emc. next up, george soros made an interesting theme attic trade in large cap financials. like citigroup, bank of america, jpmorgan chase. he got rid of those from his portfolio. and omega advisers has been performing well. this time around he made interesting trades. one of which is dollar general. and ebay. he got completely out of t-mobile usa which is still in the headlines and news for possible